Actuate Therapeutics Launches Strategic Research Initiative To Combine Elraglusib With RAS Inhibitors
Benzinga Newsdesk 7 months ago
News
The combination strategy is designed to simultaneously block proliferative signaling through RAS inhibition and disrupt tumor survival pathways via elraglusib's GSK-3β inhibition, potentially enhancing apoptotic
The combination strategy is designed to simultaneously block proliferative signaling through RAS inhibition and disrupt tumor survival pathways via elraglusib's GSK-3β inhibition, potentially enhancing apoptotic signaling beyond the threshold achieved with RAS inhibition alone.